| Gene symbol | KRAS | Synonyms | C-K-RAS, C-K-RAS, CFC2, K-RAS2A, K-RAS2B, K-RAS4A, K-RAS4B, K-Ras, K-Ras 2, KI-RAS, KRAS1, KRAS2, NS, NS3, OES, RALD, RASK2, c-Ki-ras, c-Ki-ras2 | Type of gene | protein-coding |
| Chromosome | 12 | Map location | 12p12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | KRAS proto-oncogene, GTPase | ||||
| GTO ID | GTC1939 |
| Trial ID | NCT03608631 |
| Disease | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma |
| Altered gene | KRAS |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | KrasG12D siRNA|iExosomes |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Phase I Study of Mesenchymal Stromal Cells-Derived Exosomes With KrasG12D siRNA for Metastatic Pancreas Cancer Patients Harboring KrasG12D Mutation |
| Year | 2021 |
| Country | United States |
| Company sponsor | M.D. Anderson Cancer Center |
| Other ID(s) | 2018-0126|NCI-2018-01441|2018-0126 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||